Arsenic Trioxide clinical trials
Also written Trisenox and Arsenic Sesquioxide.
How each study uses Arsenic Trioxide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Arsenic Trioxide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 25 Sept 2000 · TRISENOX · NDA 021248 (FDA, Drugs@FDA)
- European Union
- 5 Mar 2002 · Trisenox · EMEA/H/C/000388 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
116 studies that test it; most in 2004 (14)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 1998 | 3 |
| 1999 | 3 |
| 2000 | 13 |
| 2001 | 5 |
| 2002 | 8 |
| 2003 | 5 |
| 2004 | 14 |
| 2005 | 7 |
| 2006 | 1 |
| 2007 | 9 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 5 |
| 2013 | 4 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 109
Memorial Sloan Kettering Cancer Center (10) · National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (4) · Stanford University (3) · University of Miami (3) · Washington University School of Medicine (3) · The University of Texas Medical Branch, Galveston (3) · Northwestern University (3)
Often tested with
Tested in the same studies.
Ascorbic Acid (12) · Tretinoin (11) · Dexamethasone (6) · Cytarabine (6) · Thalidomide (5) · Decitabine (4) · Gemtuzumab (3) · Imatinib (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test Arsenic Trioxide, phase 3 first.
- Jun 2027A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)Phase 3 · SDK Therapeutics, Inc.
- Feb 2027Oral-ATO for TP53-mutated Myeloid MalignanciesPhase 2 · The University of Hong Kong
- Mar 2027ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.Phase 1 · Daniel Breadner
- Jul 2027Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaNot applicable · Anhui Medical University
Studies
Open first, then newest update. How each study uses Arsenic Trioxide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 118
- Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT01409161Written as Arsenic Trioxide
- Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic SyndromeRecruitingPhase 1University of Michigan Rogel Cancer CenterNCT07737769Written as Arsenic Trioxide
- Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant MedulloblastomaNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07856069Written as Arsenic Trioxide (ATO)
- Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)RecruitingPhase 1Groupe Francophone des MyelodysplasiesNCT06670222Written as Arsenic Trioxide (ATO)
- ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.Not yet recruitingPhase 1Daniel BreadnerNCT07348107Written as Arsenic Trioxide (ATO)
- A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)Not yet recruitingPhase 3SDK Therapeutics, Inc.NCT07296445Written as IV Arsenic Trioxide
- Oral-ATO for TP53-mutated Myeloid MalignanciesRecruitingPhase 2The University of Hong KongNCT06778187Written as Oral arsenic trioxide
- Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid LeukemiaEnrolling by invitationPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT03031249Written as Arsenic Trioxide
- Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M NeuroblastomaRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06933394Written as Arsenic trioxide
- Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APLRecruitingNot applicableZhejiang Provincial People's HospitalNCT06450145Written as interferon α-2b
- Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric CancerRecruitingPhase 2Yang LiNCT06088030Written as Arsenic trioxide
- Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APLRecruitingPhase 1/2Hospital Universitario Dr. Jose E. GonzalezNCT05497310Written as Arsenic trioxide
- The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cARTRecruitingPhase 1Guangzhou 8th People's HospitalNCT03980665Written as Arsenic Trioxide
- Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic LeukemiaCompletedPhase 3Technische Universität DresdenNCT02688140Written as Arsenic trioxide
- Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic LeukemiaActive, not recruitingPhase 3Children's Oncology GroupNCT02339740Written as Arsenic Trioxide
- Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic LeukemiaCompletedPhase 1SDK Therapeutics, Inc.NCT06882031Written as Treatment A: Arsenic Trioxide (ATO) Intravenous
- Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaActive, not recruitingNot applicableAnhui Medical UniversityNCT07187505Written as Arsenic Trioxide (ATO)
- Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M NeuroblastomaActive, not recruitingPhase 2Yang LiNCT03503864Written as Arsenic Trioxide
- A Study for Oral SY-2101 for Participants With Acute Promyelocytic LeukemiaSuspendedPhase 1Syros PharmaceuticalsNCT04996030Written as SY-2101
- Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)WithdrawnPhase 3Li JunminNCT03377725Written as Arsenic Trioxide
See all 118 studies that test Arsenic Trioxide →
Given beside what is tested · 9 — Arsenic Trioxide is usual care or a partner of the new treatment
- Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).RecruitingPhase 3First Affiliated Hospital Xi'an Jiaotong UniversityNCT07503730Written as ATO
- Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian CancerRecruitingPhase 1/2Xing XieNCT04518501Written as Arsenic trioxide Tablet +Fuzuloparib Capsules
- Treatment Study for Children and Adolescents With Acute Promyelocytic LeukemiaRecruitingPhase 2Associazione Italiana Ematologia Oncologia PediatricaNCT04793919Written as Arsenic Trioxide
- Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid AcidStatus unknownPhase 1First Affiliated Hospital Xi'an Jiaotong UniversityNCT05297123Written as Arsenic Trioxide
- Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDSCompletedPhase 2Fox Chase Cancer CenterNCT02190695Written as Arsenic trioxide
- Velcade, Trisenox, Vitamin C and Melphalan for Myeloma PatientsCompletedPhase 1/2M.D. Anderson Cancer CenterNCT00469209Written as Trisenox (Arsenic Trioxide)
- All-trans Retinoic Acid, and Arsenic +/- IdarubicinCompletedPhase 2M.D. Anderson Cancer CenterNCT00413166Written as Arsenic Trioxide (ATO)
- Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKIStatus unknownPhase 1Betta Pharmaceuticals Co., Ltd.NCT02066870Written as Arsenic trioxide
- Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic LeukemiaTerminatedPhase 1Northwestern UniversityNCT00985530Written as Arsenic trioxide
As the comparator · 3 — what is tested is compared with Arsenic Trioxide
- Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaRecruitingPhase 3Quetzal TherapeuticsNCT07504458Written as IV arsenic trioxide (ATO) + ATRA
- A Study for Improving the Outcome of Childhood Acute Promyeloid LeukemiaCompletedPhase 4South China Children's Leukemia GroupNCT02200978Written as ATO
- Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)Status unknownPhase 3First Affiliated Hospital Xi'an Jiaotong UniversityNCT02899169Written as Arsenic trioxide
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Codes
What other systems call Arsenic Trioxide · ClinicalTrials.gg INT006674
- MeSH (NLM) D000077237Arsenic TrioxideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) S7V92P67HOARSENIC TRIOXIDEConfirmed FDA, NLM, Wikidata
- RxNorm 18330Confirmed FDA, Wikidata
- Wikidata Q7739arsenic trioxideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1005Arsenic TrioxideConfirmed FDA, Wikidata
- DrugBank DB01169One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077237 | Arsenic Trioxide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | S7V92P67HO | ARSENIC TRIOXIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 18330 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7739 | arsenic trioxide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1005 | Arsenic Trioxide | Confirmed FDA, Wikidata |
| DrugBank | DB01169 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.